WO2015028875A3 - Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir - Google Patents

Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir Download PDF

Info

Publication number
WO2015028875A3
WO2015028875A3 PCT/IB2014/001637 IB2014001637W WO2015028875A3 WO 2015028875 A3 WO2015028875 A3 WO 2015028875A3 IB 2014001637 W IB2014001637 W IB 2014001637W WO 2015028875 A3 WO2015028875 A3 WO 2015028875A3
Authority
WO
WIPO (PCT)
Prior art keywords
darunavir
ritonavir
emtricitabine
tenofovir
dosage form
Prior art date
Application number
PCT/IB2014/001637
Other languages
French (fr)
Other versions
WO2015028875A8 (en
WO2015028875A2 (en
Inventor
Nitzan SHAHAR
Elina HARONSKY
Julia Hrakovsky
Original Assignee
Teva Pharmaceuticals Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Industries Ltd. filed Critical Teva Pharmaceuticals Industries Ltd.
Priority to CA2918707A priority Critical patent/CA2918707A1/en
Priority to MX2016002560A priority patent/MX2016002560A/en
Priority to EP14790289.4A priority patent/EP3038607A2/en
Publication of WO2015028875A2 publication Critical patent/WO2015028875A2/en
Publication of WO2015028875A3 publication Critical patent/WO2015028875A3/en
Priority to IL244107A priority patent/IL244107A0/en
Priority to US15/051,381 priority patent/US20160199396A1/en
Priority to HK16108535.7A priority patent/HK1220390A1/en
Publication of WO2015028875A8 publication Critical patent/WO2015028875A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection.
PCT/IB2014/001637 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir WO2015028875A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2918707A CA2918707A1 (en) 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
MX2016002560A MX2016002560A (en) 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.
EP14790289.4A EP3038607A2 (en) 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
IL244107A IL244107A0 (en) 2013-08-29 2016-02-14 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
US15/051,381 US20160199396A1 (en) 2013-08-29 2016-02-23 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
HK16108535.7A HK1220390A1 (en) 2013-08-29 2016-07-19 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871674P 2013-08-29 2013-08-29
US61/871,674 2013-08-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/051,381 Continuation-In-Part US20160199396A1 (en) 2013-08-29 2016-02-23 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir

Publications (3)

Publication Number Publication Date
WO2015028875A2 WO2015028875A2 (en) 2015-03-05
WO2015028875A3 true WO2015028875A3 (en) 2015-11-19
WO2015028875A8 WO2015028875A8 (en) 2016-09-01

Family

ID=51830545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/001637 WO2015028875A2 (en) 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir

Country Status (8)

Country Link
EP (1) EP3038607A2 (en)
AR (1) AR097512A1 (en)
CA (1) CA2918707A1 (en)
HK (1) HK1220390A1 (en)
IL (1) IL244107A0 (en)
MX (1) MX2016002560A (en)
TW (1) TW201542212A (en)
WO (1) WO2015028875A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015245217A1 (en) * 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
KR101777564B1 (en) 2016-05-30 2017-09-12 영남대학교 산학협력단 Tablet composition comprising tenofovir disoproxil free base and preparation method thereof
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
CN108727401A (en) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 Darunavir novel crystal forms and its preparation method and application

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064846A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2006005720A1 (en) * 2004-07-08 2006-01-19 Tibotec Pharmaceuticals Ltd. Combination of anti-hiv reverse transcriptase and protease inhibitors
EP1800681A1 (en) * 2004-09-28 2007-06-27 Coll Farma S.L. SOLID PHARMACEUTICAL COMPOSITION COMPRISING THE THIAZOLYL METHYL ESTER OF [5S-(5R*,8R*,10R*,11R*)]-10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-[2-1(1-METHYLETHYL)-4-THIAZOLYL]-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID AND PREPARATION METHOD THEREOFvvv
WO2009002829A2 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
WO2010059038A2 (en) * 2008-11-21 2010-05-27 Ultimorphix Technologies B.V Wet granulation of tenofovir, emtricitabine and efavirenz
WO2011013110A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20120283177A1 (en) * 2009-11-20 2012-11-08 Jacques Leibowitch Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (hiv)
WO2013056992A1 (en) * 2011-10-21 2013-04-25 Jagotec Ag Improvements in or relating to organic compounds
WO2013064837A1 (en) * 2011-11-03 2013-05-10 Isis Innovation Limited Multisomes: encapsulated droplet networks
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2013128467A1 (en) * 2012-03-01 2013-09-06 Hetero Research Foundation Ritonavir compositions
WO2014184553A1 (en) * 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1994004492A1 (en) 1992-08-25 1994-03-03 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
MY145265A (en) 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
PA8809601A1 (en) 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
EP2332544A1 (en) 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV)
BR112014000195A2 (en) 2011-07-07 2017-02-21 Janssen R&D Ireland darunavir formulations
WO2013057469A1 (en) 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064846A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2006005720A1 (en) * 2004-07-08 2006-01-19 Tibotec Pharmaceuticals Ltd. Combination of anti-hiv reverse transcriptase and protease inhibitors
EP1800681A1 (en) * 2004-09-28 2007-06-27 Coll Farma S.L. SOLID PHARMACEUTICAL COMPOSITION COMPRISING THE THIAZOLYL METHYL ESTER OF [5S-(5R*,8R*,10R*,11R*)]-10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-[2-1(1-METHYLETHYL)-4-THIAZOLYL]-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID AND PREPARATION METHOD THEREOFvvv
WO2009002829A2 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
WO2010059038A2 (en) * 2008-11-21 2010-05-27 Ultimorphix Technologies B.V Wet granulation of tenofovir, emtricitabine and efavirenz
WO2011013110A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20120283177A1 (en) * 2009-11-20 2012-11-08 Jacques Leibowitch Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (hiv)
WO2013056992A1 (en) * 2011-10-21 2013-04-25 Jagotec Ag Improvements in or relating to organic compounds
WO2013064837A1 (en) * 2011-11-03 2013-05-10 Isis Innovation Limited Multisomes: encapsulated droplet networks
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2013128467A1 (en) * 2012-03-01 2013-09-06 Hetero Research Foundation Ritonavir compositions
WO2014184553A1 (en) * 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions

Also Published As

Publication number Publication date
IL244107A0 (en) 2016-04-21
WO2015028875A8 (en) 2016-09-01
TW201542212A (en) 2015-11-16
EP3038607A2 (en) 2016-07-06
MX2016002560A (en) 2016-10-26
HK1220390A1 (en) 2017-05-05
CA2918707A1 (en) 2015-03-05
AR097512A1 (en) 2016-03-23
WO2015028875A2 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
EP3505519A4 (en) Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
MX2017016802A (en) Pharmaceutical formulations.
IL248095A0 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2015028875A3 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
IL243786A0 (en) Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
MX343689B (en) Darunavir combination formulations.
MX2017003928A (en) Long acting pharmaceutical compositions.
EP3590514A4 (en) Medicinal preparation
EP3694522A4 (en) Bi-layer pharmaceutical tablet formulation
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
EP3643304A4 (en) Pharmaceutical nanosuspension for the therapy of hiv infection
WO2015022560A8 (en) Stable pharmaceutical composition containing bisoprolol and ramipril
PH12017501979A1 (en) Pharmaceutical compound
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
JO3641B1 (en) Antiretroviral composition
WO2016082807A3 (en) New use of itraconazole
WO2019059868A3 (en) Pharmaceutical combinations comprising tenofovir, emtricitabine and efavirenz
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
EP3697393A4 (en) Pharmaceutical dosage forms
WO2014122671A3 (en) Solid oral compositions of saxagliptin
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
IN2014DN07895A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14790289

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2918707

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014790289

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014790289

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 244107

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/002560

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14790289

Country of ref document: EP

Kind code of ref document: A2